ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > From last june the 20th.

<< Previous

Bullboard Posts

Next >>

Post by Alex1726on Nov 08, 2024 8:02pm

111 Views

Post# 36304239

From last june the 20th.

Post by Alex1726on Jun 20, 2024 10:08pm

144 Views

Post# 36099255

The Answer Was Here All the Time: Why Anavex2-73 Can Stop AD

https://www.biotechtoinvest.com/research/2022/5/15/the-answer-was-here-all-the-time-why-anavex2-73-can-stop-alzheimers-disease

On last june 20th when i wrote this post Anavex was tradind at $3.95 U.S. it now trades at $9.24 and PMN was trading at $1.50. Promis neurosciences has never created value for shareholders.

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal